8/8/2019 4:11:28 PM
Inovio Pharma Q2 Loss/share $0.30 Vs. Loss $0.08 Year Ago
8/6/2019 4:16:44 PM
Inovio Closes $15 Mln Private Placement Of Convertible Bonds To Institutional Investors In Korea
7/25/2019 9:02:11 AM
Inovio's Positive First-in-Human MERS Vaccine Results Published In Lancet Infectious Diseases
7/10/2019 8:02:39 AM
Geneos Therapeutics Says First Patient Dosed With DNA-based, Neoantigen-Targeting Personalized Vaccine Technology
7/8/2019 9:02:02 AM
Inovio Completes Enrollment In Its Phase 2 Trial With VGX-3100
6/26/2019 9:15:04 AM
Inovio Closes Enrollment Of VGX-3100 Phase 3 Trial For Treatment Of HPV-Related Cervical Pre-cancer
6/10/2019 9:04:16 AM
Inovio Bags $8.14 Mln Award To Support Further Development Of Commercial Skin Delivery Device
5/21/2019 9:02:37 AM
Inovio Doses Subjects In Phase 1, First-in-human Clinical Trial To Evaluate INO-4500
5/9/2019 4:10:27 PM
Inovio Pharma Q1 Loss/share $0.30 Vs. Loss $0.36 Year Ago
5/6/2019 9:10:31 AM
Inovio Gets European Medicines Agency Certification For Quality And Non-Clinical Data For Phase 3 Product, VGX-3100
4/18/2019 9:03:29 AM
Inovio Publishes Cancer Killing Data Of Its Transformative DNA-encoded Bi-specific T Cell Engagers
4/8/2019 9:02:45 AM
Inovio Pharma Says Achieves Third Cancer Indication Milestone For MEDI0457 Phase 2 Development
4/2/2019 7:46:59 AM
Inovio Says Novel DNA-Encoded Bi-specific T Cell Engagers Generated Potent Anti-tumor Activities In Preclinical Study
4/1/2019 7:48:04 AM
Inovio Completes Enrollment Ahead Of Schedule In Immuno-Oncology Study For Glioblastoma
3/25/2019 7:46:03 AM
Inovio Pharmaceuticals Appoints Ann Miller To Its Board